Gene therapy for pulmonary diseases.

M. A. Rosenfeld, G. Ronald, Ronald Crystal

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The common fatal hereditary disorders, alpha 1-antitrypsin (alpha 1AT) deficiency and cystic fibrosis (CF), are clinical models for the common lung diseases, emphysema and chronic bronchitis, respectively. Both are potentially amenable to therapeutic intervention by gene therapy, in which the relevant gene is used to modify cells of the affected individual. Although the gene therapy strategies for these diseases are conceptually quite different, a promising approach for both is the in vivo administration of a recombinant replication deficient adenovirus vector containing a normal copy of the abnormal gene. If the goal is to express the normal extracellular anti-protease alpha 1 AT, the route of administration could be directly into the lung, liver or vascular endothelium. If the goal is to express the normal transmembrane protein defective in CF epithelial cells, the new gene will need to be delivered directly to the affected cells. The feasibility of these approaches has been demonstrated in vitro and in vivo in experimental animals.

Original languageEnglish
Pages (from-to)677-680
Number of pages4
JournalPathologie Biologie
Volume41
Issue number8
Publication statusPublished - 1 Oct 1993
Externally publishedYes

Fingerprint

Gene therapy
Pulmonary diseases
Genetic Therapy
Lung Diseases
Genes
Cystic Fibrosis
alpha 1-Antitrypsin Deficiency
alpha 1-Antitrypsin
Chronic Bronchitis
Emphysema
Vascular Endothelium
Adenoviridae
Liver
Animals
Peptide Hydrolases
Epithelial Cells
Lung
Proteins
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Rosenfeld, M. A., Ronald, G., & Crystal, R. (1993). Gene therapy for pulmonary diseases. Pathologie Biologie, 41(8), 677-680.

Gene therapy for pulmonary diseases. / Rosenfeld, M. A.; Ronald, G.; Crystal, Ronald.

In: Pathologie Biologie, Vol. 41, No. 8, 01.10.1993, p. 677-680.

Research output: Contribution to journalReview article

Rosenfeld, MA, Ronald, G & Crystal, R 1993, 'Gene therapy for pulmonary diseases.', Pathologie Biologie, vol. 41, no. 8, pp. 677-680.
Rosenfeld MA, Ronald G, Crystal R. Gene therapy for pulmonary diseases. Pathologie Biologie. 1993 Oct 1;41(8):677-680.
Rosenfeld, M. A. ; Ronald, G. ; Crystal, Ronald. / Gene therapy for pulmonary diseases. In: Pathologie Biologie. 1993 ; Vol. 41, No. 8. pp. 677-680.
@article{8004ee454b374c4ebe156aa862670782,
title = "Gene therapy for pulmonary diseases.",
abstract = "The common fatal hereditary disorders, alpha 1-antitrypsin (alpha 1AT) deficiency and cystic fibrosis (CF), are clinical models for the common lung diseases, emphysema and chronic bronchitis, respectively. Both are potentially amenable to therapeutic intervention by gene therapy, in which the relevant gene is used to modify cells of the affected individual. Although the gene therapy strategies for these diseases are conceptually quite different, a promising approach for both is the in vivo administration of a recombinant replication deficient adenovirus vector containing a normal copy of the abnormal gene. If the goal is to express the normal extracellular anti-protease alpha 1 AT, the route of administration could be directly into the lung, liver or vascular endothelium. If the goal is to express the normal transmembrane protein defective in CF epithelial cells, the new gene will need to be delivered directly to the affected cells. The feasibility of these approaches has been demonstrated in vitro and in vivo in experimental animals.",
author = "Rosenfeld, {M. A.} and G. Ronald and Ronald Crystal",
year = "1993",
month = "10",
day = "1",
language = "English",
volume = "41",
pages = "677--680",
journal = "Current Research in Translational Medicine",
issn = "2452-3186",
publisher = "Elsevier Masson",
number = "8",

}

TY - JOUR

T1 - Gene therapy for pulmonary diseases.

AU - Rosenfeld, M. A.

AU - Ronald, G.

AU - Crystal, Ronald

PY - 1993/10/1

Y1 - 1993/10/1

N2 - The common fatal hereditary disorders, alpha 1-antitrypsin (alpha 1AT) deficiency and cystic fibrosis (CF), are clinical models for the common lung diseases, emphysema and chronic bronchitis, respectively. Both are potentially amenable to therapeutic intervention by gene therapy, in which the relevant gene is used to modify cells of the affected individual. Although the gene therapy strategies for these diseases are conceptually quite different, a promising approach for both is the in vivo administration of a recombinant replication deficient adenovirus vector containing a normal copy of the abnormal gene. If the goal is to express the normal extracellular anti-protease alpha 1 AT, the route of administration could be directly into the lung, liver or vascular endothelium. If the goal is to express the normal transmembrane protein defective in CF epithelial cells, the new gene will need to be delivered directly to the affected cells. The feasibility of these approaches has been demonstrated in vitro and in vivo in experimental animals.

AB - The common fatal hereditary disorders, alpha 1-antitrypsin (alpha 1AT) deficiency and cystic fibrosis (CF), are clinical models for the common lung diseases, emphysema and chronic bronchitis, respectively. Both are potentially amenable to therapeutic intervention by gene therapy, in which the relevant gene is used to modify cells of the affected individual. Although the gene therapy strategies for these diseases are conceptually quite different, a promising approach for both is the in vivo administration of a recombinant replication deficient adenovirus vector containing a normal copy of the abnormal gene. If the goal is to express the normal extracellular anti-protease alpha 1 AT, the route of administration could be directly into the lung, liver or vascular endothelium. If the goal is to express the normal transmembrane protein defective in CF epithelial cells, the new gene will need to be delivered directly to the affected cells. The feasibility of these approaches has been demonstrated in vitro and in vivo in experimental animals.

UR - http://www.scopus.com/inward/record.url?scp=0027672228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027672228&partnerID=8YFLogxK

M3 - Review article

C2 - 8290311

AN - SCOPUS:0027672228

VL - 41

SP - 677

EP - 680

JO - Current Research in Translational Medicine

JF - Current Research in Translational Medicine

SN - 2452-3186

IS - 8

ER -